Ultralife (NASDAQ:ULBI) Releases Quarterly Earnings Results, Misses Expectations By $0.18 EPS

Ultralife (NASDAQ:ULBI) issued its quarterly earnings results on Friday. The technology company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.18), Zacks reports. Ultralife had a positive return on equity of 3.10% and a negative net margin of 3.09%.

Here are the key takeaways from Ultralife’s conference call:

• Q1 revenue was $47.4 million with an operating loss of $0.2 million and a net loss of $0.5 million (‑$0.03/sh), attributed to shipment timing, Middle East delivery delays, plant reorganizations, weather-related interruptions, and pre‑revenue staffing and consulting costs.
• Consolidated gross margin dropped to 21.3% (down 380 bps) and gross profit fell 20.7% year‑over‑year, driven largely by lost production days (Newark substation failure and a 16‑day equivalent impact at Raynham during ERP/inventory transition), higher energy costs, and unfavorable sales mix/tariffs.
• The company exited Q1 with a record backlog of $115.1 million (up 21% YoY), representing 61% of trailing‑12‑month sales and including over $12 million of new‑product backlog, providing stronger near‑term revenue visibility.
• Management is investing in product development and vertical integration (Electrochem), expects to more than double internal cell usage, shipped the first conformal wearable battery order with > $8 million backlog, and won a $4 million multi‑year award—actions intended to stabilize Communications Systems revenue and lift gross margins.

Ultralife Stock Performance

Shares of ULBI stock traded down $1.08 during trading hours on Friday, hitting $5.97. 131,366 shares of the company were exchanged, compared to its average volume of 44,552. The firm has a fifty day simple moving average of $6.64 and a 200 day simple moving average of $6.30. The company has a current ratio of 2.83, a quick ratio of 1.39 and a debt-to-equity ratio of 0.35. Ultralife has a 52-week low of $4.78 and a 52-week high of $9.52. The stock has a market capitalization of $99.46 million, a price-to-earnings ratio of -16.58 and a beta of 0.74.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Lazard Asset Management LLC boosted its holdings in Ultralife by 1,650.0% in the 2nd quarter. Lazard Asset Management LLC now owns 5,565 shares of the technology company’s stock worth $49,000 after buying an additional 5,247 shares during the period. Empowered Funds LLC bought a new position in Ultralife in the 4th quarter worth approximately $44,000. Prelude Capital Management LLC bought a new position in Ultralife in the 3rd quarter worth approximately $71,000. Bank of America Corp DE boosted its holdings in Ultralife by 30.7% in the 4th quarter. Bank of America Corp DE now owns 12,067 shares of the technology company’s stock worth $90,000 after buying an additional 2,836 shares during the period. Finally, Jane Street Group LLC bought a new position in Ultralife in the 4th quarter worth approximately $75,000. 30.68% of the stock is owned by institutional investors.

Ultralife Company Profile

Ultralife Corporation (NASDAQ: ULBI) develops, manufactures and sells a broad range of energy and communications products for defense, medical, automotive and consumer electronics markets. The company operates through two primary segments: Power Systems and Communications Systems. In its Power Systems segment, Ultralife produces lithium-ion rechargeable cells and battery packs, primary lithium batteries, alkaline and rechargeable battery packs, chargers and battery accessories designed to meet demanding performance and safety requirements.